Soleno Therapeutics (NASDAQ:SLNO) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research began coverage on shares of Soleno Therapeutics (NASDAQ:SLNO) in a report published on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $75.00 price objective on the stock.

Other analysts also recently issued reports about the company. Lifesci Capital upgraded Soleno Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 10th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $106.00 price target (down previously from $123.00) on shares of Soleno Therapeutics in a report on Wednesday, November 5th. Oppenheimer increased their price target on shares of Soleno Therapeutics from $105.00 to $110.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Wall Street Zen upgraded Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $111.46.

Soleno Therapeutics Trading Up 2.7%

Shares of Soleno Therapeutics stock opened at $48.54 on Tuesday. Soleno Therapeutics has a 52-week low of $41.50 and a 52-week high of $90.32. The stock has a market cap of $2.61 billion, a PE ratio of -11.72 and a beta of -2.92. The firm has a 50-day moving average of $59.33 and a 200-day moving average of $71.62. The company has a debt-to-equity ratio of 0.21, a quick ratio of 15.01 and a current ratio of 15.13.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.08 by $0.39. The business had revenue of $66.02 million during the quarter, compared to the consensus estimate of $47.46 million. As a group, sell-side analysts forecast that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Trading of Soleno Therapeutics

Hedge funds have recently made changes to their positions in the company. Arizona State Retirement System lifted its stake in shares of Soleno Therapeutics by 9.2% in the first quarter. Arizona State Retirement System now owns 7,380 shares of the company’s stock worth $527,000 after acquiring an additional 620 shares during the period. Mutual of America Capital Management LLC bought a new stake in shares of Soleno Therapeutics in the 1st quarter valued at $5,186,000. Victory Capital Management Inc. acquired a new stake in shares of Soleno Therapeutics during the first quarter worth $288,000. Y Intercept Hong Kong Ltd acquired a new position in Soleno Therapeutics in the first quarter valued at $2,888,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Soleno Therapeutics during the first quarter valued at $2,608,000. 97.42% of the stock is owned by institutional investors and hedge funds.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.